Kerri Schoedel, Ph.D. has been promoted to scientific director, clinical pharmacology for Kendle's Early Stage unit in Toronto. Dr. Schoedel will provide overall scientific direction and leadership to the clinical pharmacology group, as well as lead strategic planning and policy development as it relates to scientific assessment. She is experienced in the field of psychopharmacology and the assessment of drug abuse liability, and also has experience in pre-clinical and clinical studies and working with regulatory authorities.
“I am thrilled to announce Kerri’s appointment to scientific director, clinical pharmacology,” said Phil Davies, vice president, Early Stage. “We look forward to Kerri's continued contributions and leadership as Kendle further advances its established position as the leading authority in Early Stage psychopharmacology and human abuse liability. This appointment also reinforces our commitment to grow and advance our global Early Stage team and capabilities.”
Dr. Schoedel joined DecisionLine, formerly Ventana Clinical Research Corp. and now part of Kendle, in 2004. She began her career as a research scientist and was promoted to senior research scientist. In these positions, she was responsible for providing scientific input to project teams, assisted with clinical study and protocol design and provided project management for clinical research projects.